You’ve Read the News - Now Find the Expert
Click to discover leading experts on 50,000+ topics for media, events & more.
Discover Experts on 50,000+ TopicsConnect for media, speaking, expert witness inquiries & more.
Experts on 50,000+ TopicsClick to connect to media sources & more.
Powered by:
Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug
cnbc.com/2025/03/10/novo-nordisk-shares-fall-after-cagrisema-weight-loss-drug-trial-result.html
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks.
The company's stock was down 5.52% at 11:10 a.m.…
This story appeared on cnbc.com, 2025-03-10 11:11:05.